Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809R I Fisher, B W Dana, M LeBlanc, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyR I Fisher, E R Gaynor, S Dahlberg, et al.Blood|May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.The Journal of Orthopaedic and Sports Physical Therapy|May 23, 2018
Quadriceps Rate of Torque Development and Disability in Persons With Tibiofemoral OsteoarthritisBrittney A Luc-Harkey, J Troy Blackburn, Eric D Ryan, et al.Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selectionShelly S Lo, Patricia B Mumby, John Norton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group StudyE R Gaynor, J M Unger, T P Miller, et al.Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.Pageof 7